Bristol Execs
Executive Summary
Effective Jan. 1, Exec VP and Chief Financial Officer Michael Autera will head the firm's nutritional and health care businesses, which are comprised of Mead Johnson (nutritionals), Convatec (ostomy and wound care products), Zimmer (orthopedic devices and surgical instruments) and Linvatec (least invasive surgery products). Autera will remain CFO until a replacement is named. Also on Jan. 1, Senior VP William Flatley "will assume responsibility for business strategy, the company's productivity enhancement initiatives and coordination of the restructuring effort of the corporate staff organization." Flatley will continue to be responsible for corporate hospital accounts and group purchasers in the drug and device fields. Autera and Flatley both will report to Bristol-Myers Squibb President Charles Heimbold, who becomes chief executive officer on Jan. 1.
|
Effective Jan. 1, Exec VP and Chief Financial Officer Michael
Autera will head the firm's nutritional and health care businesses,
which are comprised of Mead Johnson (nutritionals), Convatec
(ostomy and wound care products), Zimmer (orthopedic devices and
surgical instruments) and Linvatec (least invasive surgery
products). Autera will remain CFO until a replacement is named.
Also on Jan. 1, Senior VP William Flatley "will assume
responsibility for business strategy, the company's productivity
enhancement initiatives and coordination of the restructuring
effort of the corporate staff organization." Flatley will continue
to be responsible for corporate hospital accounts and group
purchasers in the drug and device fields. Autera and Flatley both
will report to Bristol-Myers Squibb President Charles Heimbold, who
becomes chief executive officer on Jan. 1. |